BWAY Brainsway

BrainsWay Debuts “#TheRealOCD” Campaign and Video on Obsessive-Compulsive Disorder (OCD)

BrainsWay Debuts “#TheRealOCD” Campaign and Video on Obsessive-Compulsive Disorder (OCD)
EN
13/10/2020

Underlying

BWAYBrainsway

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Brainsway

 PRESS RELEASE
Free
BWAY BRAINSWAY

BrainsWay Announces New Minority-Stake Investment in Canadian Provider...

BrainsWay Announces New Minority-Stake Investment in Canadian Provider, BrainStim Health Inc. BrainsWay continues to actively evaluate similar investments in leading North American mental health providers to raise awareness and expand access to transformative care BURLINGTON, Mass. and JERUSALEM, Feb. 19, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced it has entered into a strategic equity financing agreement with BrainStim Health...

February 19, 2026 1 EN
 PRESS RELEASE
Free
BWAY BRAINSWAY

BrainsWay Reports Cigna’s Evernorth Behavioral Health to Eliminate Pri...

BrainsWay Reports Cigna’s Evernorth Behavioral Health to Eliminate Prior Authorization Requirements for TMS Coverage, Accelerating Access to Care BURLINGTON, Mass. and JERUSALEM, Feb. 18, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive brain stimulation technologies, today commented on the recent  issued by Evernorth® Behavioral Health, Inc., a division of the Cigna Group, which serves over 18 million covered lives across 12 states, that it will no longer require prior authorization for transcranial magn...

February 18, 2026 1 EN
 PRESS RELEASE
Free
BWAY BRAINSWAY

BrainsWay Announces Change in ADS-to-Ordinary Share Ratio

BrainsWay Announces Change in ADS-to-Ordinary Share Ratio Change in ADS ratio aimed at simplifying comparisons to ordinary shares traded on the Tel Aviv Stock Exchange, while boosting liquidity and access for U.S. investors BURLINGTON, Mass. and JERUSALEM, Feb. 17, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive brain stimulation technologies, today announced that its Board of Directors approved a plan to change to the ratio of its American Depositary Shares (ADSs) listed on the Nasdaq Capital Market (...

February 17, 2026 1 EN
 PRESS RELEASE
Free
BWAY BRAINSWAY

BrainsWay Announces Draft Coverage Policy from Highmark® for Accelerat...

BrainsWay Announces Draft Coverage Policy from Highmark® for Accelerated Deep TMS™ New draft policy from Highmark Blue Cross Blue Shield extends to both adolescent and adult depression patients BURLINGTON, Mass. and JERUSALEM, Jan. 21, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive brain stimulation technologies, today announced that Highmark Blue Cross Blue Shield®, a company with over seven million covered lives that primarily serves Pennsylvania, Delaware, West Virginia, and parts of New York, has ...

January 21, 2026 1 EN
 PRESS RELEASE
Free
BWAY BRAINSWAY

BrainsWay Announces FDA Approval of Neurolief’s Proliv™Rx Neuromodulat...

BrainsWay Announces FDA Approval of Neurolief’s Proliv™Rx Neuromodulation System for Major Depressive Disorder (MDD) BrainsWay’s strategic investment in Neurolief paved the way for the first and only FDA approved at-home neuromodulation device with Class III Premarket Approval labeling for MDD patients who failed one or more prior antidepressants BURLINGTON, Mass. and JERUSALEM, Jan. 12, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive brain stimulation technologies, today announced that the U.S. Food a...

January 12, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch